Kirstin A Zettlitz

List of Publications by Year
in descending order

39 papers	1,359 citations	331670 21 h-index	434195 31 g-index
40 all docs	40 docs citations	40 times ranked	2200 citing authors

#	Article	IF	Citations
1	An Effective Immuno-PET Imaging Method to Monitor CD8-Dependent Responses to Immunotherapy. Cancer Research, 2016, 76, 73-82.	0.9	265
2	Engineered antibody fragments for immuno-PET imaging of endogenous CD8$^+$ T cells in vivo. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 1108-1113.	7.1	148
3	Immuno-PET of Murine T Cell Reconstitution Postadoptive Stem Cell Transplantation Using Anti-CD4 and Anti-CD8 Cys-Diabodies. Journal of Nuclear Medicine, 2015, 56, 1258-1264.	5.0	104
4	N-Glycosylation as Novel Strategy to Improve Pharmacokinetic Properties of Bispecific Single-chain Diabodies. Journal of Biological Chemistry, 2008, 283, 7804-7812.	3.4	84
5	The effects of affinity and valency of an albumin-binding domain (ABD) on the half-life of a single-chain diabody-ABD fusion protein. Protein Engineering, Design and Selection, 2010, 23, 827-834.	2.1	80
6	ImmunoPET Imaging of Murine CD4+ T Cells Using Anti-CD4 Cys-Diabody: Effects of Protein Dose on T Cell Function and Imaging. Molecular Imaging and Biology, 2017, 19, 599-609.	2.6	61
7	Immuno-PET in Inflammatory Bowel Disease: Imaging CD4-Positive T Cells in a Murine Model of Colitis. Journal of Nuclear Medicine, 2018, 59, 980-985.	5.0	54
8	Quantitative ImmunoPET of Prostate Cancer Xenografts with ^{89}Zr- and ^{124}I-Labeled Anti-PSCA A11 Minibody. Journal of Nuclear Medicine, 2014, 55, 452-459.	5.0	51
9	ATROSAB, a humanized antagonistic anti-tumor necrosis factor receptor one-specific antibody. MAbs, 2010, 2, 639-647.	5.2	49
10	ImmunoPET of Malignant and Normal B Cells with 89Zr- and 124I-Labeled Obinutuzumab Antibody Fragments Reveals Differential CD20 Internalization *In Vivo*. Clinical Cancer Research, 2017, 23, 7242-7252.	7.0	45
11	Fluorescent Image–Guided Surgery with an Anti-Prostate Stem Cell Antigen (PSCA) Diabody Enables Targeted Resection of Mouse Prostate Cancer Xenografts in Real Time. Clinical Cancer Research, 2016, 22, 1403-1412.	7.0	40
12	Dual-Modality Immuno-PET and Near-Infrared Fluorescence Imaging of Pancreatic Cancer Using an Anti–Prostate Stem Cell Antigen Cys-Diabody. Journal of Nuclear Medicine, 2018, 59, 1398-1405.	5.0	40
13	Dual-Modality ImmunoPET/Fluorescence Imaging of Prostate Cancer with an Anti-PSCA Cys-Minibody. Theranostics, 2018, 8, 5903-5914.	10.0	33
14	Anti-MET ImmunoPET for Non–Small Cell Lung Cancer Using Novel Fully Human Antibody Fragments. Molecular Cancer Therapeutics, 2014, 13, 2607-2617.	4.1	29
15	Applications of ImmunoPET: Using 124I-Anti-PSCA A11 Minibody for Imaging Disease Progression and Response to Therapy in Mouse Xenograft Models of Prostate Cancer. Clinical Cancer Research, 2014, 20, 6367-6378.	7.0	29
16	Enhanced immunoPET of ALCAM-positive colorectal carcinoma using site-specific 64Cu-DOTA conjugation. Protein Engineering, Design and Selection, 2014, 27, 317-324.	2.1	27
17	A Dual-Modality Linker Enables Site-Specific Conjugation of Antibody Fragments for ^{18}F-Immuno-PET and Fluorescence Imaging. Journal of Nuclear Medicine, 2019, 60, 1467-1473.	5.0	24
18	A novel expression and purification system for the production of enzymatic and biologically active human granzyme B. Journal of Immunological Methods, 2011, 371, 8-17.	1.4	23

#	Article	IF	Citations
19	18F-labeled anti-human CD20 cys-diabody for same-day immunoPET in a model of aggressive B cell lymphoma in human CD20 transgenic mice. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 489-500.	6.4	23
20	Near-Infrared Dye-Labeled Anti-Prostate Stem Cell Antigen Minibody Enables Real-Time Fluorescence Imaging and Targeted Surgery in Translational Mouse Models. Clinical Cancer Research, 2019, 25, 188-200.	7.0	23
21	A fully human scFv phage display library for rapid antibody fragment reformatting. Protein Engineering, Design and Selection, 2015, 28, 307-316.	2.1	22
22	Murine endoglin-specific single-chain Fv fragments for the analysis of vascular targeting strategies in mice. Journal of Immunological Methods, 2008, 339, 90-98.	1.4	17
23	Monovalent TNF receptor 1-selective antibody with improved affinity and neutralizing activity. MAbs, 2019, 11, 166-177.	5.2	15
24	Development and characterization of an Î±vÎ²6-specific diabody and a disulfide-stabilized Î±vÎ²6-specific cys-diabody. Nuclear Medicine and Biology, 2015, 42, 945-957.	0.6	12
25	An anti-TNFR1 scFv-HSA fusion protein as selective antagonist of TNF action. Protein Engineering, Design and Selection, 2013, 26, 581-587.	2.1	10
26	Evaluation of [131I]I- and [177Lu]Lu-DTPA-A11 Minibody for Radioimmunotherapy in a Preclinical Model of PSCA-Expressing Prostate Cancer. Molecular Imaging and Biology, 2020, 22, 1380-1391.	2.6	10
27	On-demand radiosynthesis of N-succinimidyl-4-[18F]fluorobenzoate ([18F]SFB) on an electrowetting-on-dielectric microfluidic chip for 18F-labeling of protein. RSC Advances, 2019, 9, 32175-32183.	3.6	8
28	Tri-functional platform for construction of modular antibody fragments for in vivo 18F-PET or NIRF molecular imaging. Chemical Science, 2020, 11, 1832-1838.	7.4	8
29	Humanization of a Mouse Monoclonal Antibody Directed Against a Cell Surface-Exposed Epitope of Membrane-Associated Heat Shock Protein 70 (Hsp70). Molecular Biotechnology, 2010, 46, 265-278.	2.4	6
30	[89Zr]A2cDb Immuno-PET of Prostate Cancer in a Human Prostate Stem Cell Antigen Knock-in (hPSCA KI) Syngeneic Model. Molecular Imaging and Biology, 2020, 22, 367-376.	2.6	6
31	Detection of antibody therapy-induced anti-tumor immune responses using anti-CD8 immuno-pet. , 2015, 3, .		3
32	Protein A/G Chromatography. , 2010, , 531-535.		2
33	Response to the Letter of Dr. Gabriele Multhoff. Molecular Biotechnology, 2010, 46, 209-209.	2.4	0
34	2027 DEVELOPMENT AND VALIDATION OF A FLUORESCENT LABELED ANTIBODY FRAGMENT FOR IMAGE-GUIDED PROSTATE CANCER SURGERY. Journal of Urology, 2013, 189, .	0.4	0
35	Generation of Heavy and Light Chains (Chimeric Antibodies). , 2010, , 307-317.		0
36	Abstract 1856: Dual-modality immunoPET/fluorescence imaging of prostate cancer utilizing89Zr- or124I-Cy5.5-anti-PSCA cys-minibody. , 2017, , .		0

#	Article	IF	Citations
37	Abstract A52: Efficacy of new developed N-cadherin monoclonal antibodies in combination with enzalutamide against castration-resistant prostate cancer. , 2018, , .		0
38	Abstract 1775: Development of fully humanized N-cadherin monoclonal antibodies for treatment of castration resistant prostate cancer. , 2018, , .		0
39	89Zr-ImmunoPET Shows Therapeutic Efficacy of Anti-CD20-IFNÎ± Fusion Protein in a Murine B-cell Lymphoma Model. Molecular Cancer Therapeutics, 2022, 21, 607-615.	4.1	0